98%
921
2 minutes
20
Objective: Achieving remission in severe asthma holds paramount importance in elevating patient quality of life and reducing both individual and societal burdens associated with this chronic condition. This study centers on identifying pivotal patient-relevant endpoints through standardized, reproducible methods, while also developing a patient-centric definition of remission, essential for effective disease management.
Methods: A discrete choice experiment (DCE) was conducted to assess patients' perceptions on the four primary criteria for defining severe asthma remission, as outlined by the SANI survey. Additionally, it investigated the correlation between these perceptions and improvements in the doctor-patient therapeutic alliance during treatment decision-making.
Results: 249 patients (70% aged between 31-60, 59% women and 82% without other pathologies requiring corticosteroids) prioritize the use of oral corticosteroids (OCS, 48%) and the Asthma Control Test (ACT, 27%) in defining their condition, ranking these above lung function and exacerbations. This preference for OCS stems from its direct role in treatment, tangible tracking, immediate symptom relief, and being a concrete measure of disease severity compared to the less predictable and quantifiable exacerbations.
Conclusions: This study explores severe asthma remission from patients' perspectives using clinician-evaluated parameters. The DCE revealed that most patients highly value OCS and the ACT, prefer moderate improvement, and avoid cortisone cycles. No definitive preference was found for lung function status. Integrating patient-reported information with professional insights is crucial for effective management and future research. Personalized treatment plans focusing on patient preferences, adherence, and alternative therapies aim to achieve remission and enhance quality of life.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/02770903.2024.2366523 | DOI Listing |
Background: Current definitions of clinical remission (CR) use different tools and thresholds to define good asthma control. Their differential impact on CR rates in severe asthma is poorly understood.
Methods: Data from a real-world study in patients with SEA treated with benralizumab (imPROve Asthma, NCT04184284, total number of patients: 244 patients) were analyzed.
Curr Opin Allergy Clin Immunol
August 2025
Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark.
Purpose Of Review: The potential of allergen immunotherapy (AIT) to prevent allergic airway disease progression are demonstrated. Though not all patients benefit equally, there is limited research on which patients may benefit most.In this article, we focus on factors that may influence the risk of progression and their influence on the preventive effects of AIT, and whether some patients may benefit more than others may.
View Article and Find Full Text PDFJ Allergy Clin Immunol Pract
September 2025
Division of Pulmonary, Critical Care, and Sleep Medicine, National Jewish Health, Denver, Colorado, USA. Electronic address:
Background: Several real-world cohorts and numerous case reports investigating benralizumab outcomes in eosinophilic granulomatosis with polyangiitis have been published. These studies complement the limited clinical trial data available by providing early insights on benralizumab use in a broader, real-world population.
Objective: The objective of this systematic literature review (SLR) was to provide an overview of the real-world outcomes of benralizumab in EGPA.
J Allergy Clin Immunol Pract
September 2025
Wellcome Wolfson Institute for Experimental Medicine, Queen's University Belfast, UK; Belfast Health and Social Care Trust, Belfast, UK.
Background: The aim of biologic therapies in severe asthma is inhibition of T2 inflammatory pathways.
Objective: We hypothesized that patients who achieve complete suppression of IL-5 & IL4/IL13 pathways with biologic therapy (FeNO <20ppb & blood eosinophil count (BEC) <0.15x10ˆ9, 'biological remission') would have better outcomes than patients with incomplete suppression of T2 biology.
Vestn Otorinolaringol
September 2025
Pirogov Russian National Research Medical University, Moscow, Russia.
This article is devoted to the problem of the effectiveness of therapy of recurrent polyposis rhinosinusitis and the choice of the most effective drug from the group of monoclonal antibodies. The wide prevalence of the disease, as well as the low level of effectiveness of existing treatment methods, such as glucocorticosteroid (topical and topical) therapy, antibacterial therapy and available surgical methods of treatment (polypotomy, endoscopic polysinusitomy) allow us to conclude that the existing methods of treatment for recurrent polyposis process do not allow to achieve a stable positive result. Various undesirable phenomena with prolonged use of steroidal drugs, as well as the need for repeated rhinosinusosurgery in case of recurrence of this process, make doctors-otorhinolaryngologists around the world to look for new treatment options for polyposis rhinosinusitis, one of these methods is the use of monoclonal antibodies.
View Article and Find Full Text PDF